Seoulin Bioscience Co.Ltd (038070) — Capital Reinvestment Ratio

Latest as of December 2025: 0.02x

Seoulin Bioscience Co.Ltd (038070) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow (₩631.76 Million) in capital expenditures (₩10.90 Million). Check Seoulin Bioscience Co.Ltd (038070) tangible net worth to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

₩631.76 Million
KRW

Capital Expenditures

₩10.90 Million
KRW

Data as of

Dec 2025
Most recent filing

Seoulin Bioscience Co.Ltd Capital Reinvestment Ratio (2013–2025)

This chart tracks Seoulin Bioscience Co.Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see Seoulin Bioscience Co.Ltd cash flow conversion.

Annual Capital Reinvestment Ratio for Seoulin Bioscience Co.Ltd (2013–2025)

Year-by-year Capital Reinvestment Ratio for Seoulin Bioscience Co.Ltd from 2013 to 2025. See Seoulin Bioscience Co.Ltd (038070) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2025 0.11x ₩4.76 Billion ₩507.47 Million ▼ -89.8%
2023 1.05x ₩930.57 Million ₩974.21 Million ▲ +459.1%
2021 0.19x ₩8.92 Billion ₩1.67 Billion ▲ +71.9%
2020 0.11x ₩3.68 Billion ₩401.34 Million ▲ +196.1%
2019 0.04x ₩7.32 Billion ₩269.29 Million ▼ -62.4%
2018 0.10x ₩4.17 Billion ₩408.02 Million ▼ -98.5%
2017 6.71x ₩1.30 Billion ₩8.73 Billion ▲ +156.1%
2016 2.62x ₩2.76 Billion ₩7.21 Billion ▲ +188.0%
2015 0.91x ₩4.12 Billion ₩3.74 Billion ▲ +227.0%
2014 0.28x ₩2.74 Billion ₩761.57 Million ▲ +2367.3%
2013 0.01x ₩4.94 Billion ₩55.65 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow